The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer

BJU International

Volumn 118, Issue , 2016, Pages 49-55

  Meredith, Greta ^a   Wong, David ^b   Yaxley, John ^a   Coughlin, Geoff ^a   Thompson, Les ^a   Kua, Boon ^a   Gianduzzo, Troy ^a  

^a WESLEY HOSPITAL   (Australia)

^b Wesley Medical Centre   (Australia)

Author keywords

prostate cancer; PSMA PET CT; recurrence

Indexed keywords

CONTRAST MEDIUM; GALLIUM PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; UNCLASSIFIED DRUG; GALLIUM; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; AUSTRALIA; BLOOD; DIAGNOSTIC IMAGING; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AUSTRALIA; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84994320615     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13616     Document Type: Article

References (23)

1. Seigel RL, Miller KD, Jemal J. Cancer Statistics 2016. CA Cancer J Clin 2016; 66: 7–30
2. Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124–37
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–7
4. Van Poppel H, Vekemans K, Da Pozzo L et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 2006; 42: 1062–7
5. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004; 7: 211–16
6. Cookson MS, Aus G, Burnett AL et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540–5
7. Furubayashi N, Negishi T, Kashiwagi E et al. Usefulness of ultra-sensitive prostate-specific antigen following radical prostatectomy. Mol Clin Oncol 2014; 2: 851–7
8. Schmid DT, John H, Zweifel R et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235: 623–8
9. Castellucci P, Ceci F, Graziani T et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med 2014; 55: 1424–9
10. Igerc I, Kohlfürst S, Gallowitsch HJ et al. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 976–83
11. Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11–20
12. Afshar-Oromieh A, Malcher A, Eder M et al. PET imaging with a [68 Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486–95
13. Ghosh A. Heston WD Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528–39
14. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68 Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012; 39: 1085–6
15. Eder M, Schäfer M, Bauder-Wüst U et al. 68 Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23: 688–97
16. Eiber M, Maurer T, Souvatzoglou M et al. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668–74
17. 68Ga–Prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol in press 2016; in press
18. European Association of Urology. Guidelines on prostate cancer, 2015. http://uroweb.org/guideline/prostate-cancer/. Accessed 10 June 16
19. Winter A, Henke RP, Wawroschek F. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up. BMC Urol 2015; 15: 10
20. Miralbell R, Buchegger F. PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy? Eur J Nucl Med Mol Imaging 2014; 41: 1267–9
21. James ND, Sydes MR, Mason MD et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol, 2015; (Suppl; abstr 5001).
22. Yossepowitch O, Briganti A, Eastham JA et al. Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol 2014; 65: 303–13
23. Budaus L, Leyh-Bannurah SR, Salomon G et al. Initial experience of 68 Ga-PS